Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells

Galectin 3 (LGALS3) expression is prognostic for poor survival in acute myeloid leukemia (AML) patients. GCS-100 is a novel galectin inhibitor that may prove useful for AML therapy. In this study, we found GCS-100 induced apoptosis in AML cells. The agent reduced MCL-1 expression suggesting GCS-100...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biochim Biophys Acta
Autores principales: Ruvolo, Peter P., Ruvolo, Vivian R., Benton, Christopher B., AlRawi, Ahmed, Burks, Jared K., Schober, Wendy, Rolke, James, Tidmarsh, George, Hail, Numsen, Davis, R. Eric, Andreeff, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775369/
https://ncbi.nlm.nih.gov/pubmed/26704388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbamcr.2015.12.008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares